| Drug or drug class | Prick test | Intradermal test h | Patch test |
|---|---|---|---|
| β-Lactam antibiotics | |||
| Penicilloyl poly-L-lysine | 5x10-5 mM | 5x10-5 mM | NA |
| Minor determinant mixture | 2x10-2 mM | 2x10-2 mM | NA |
| Benzylpenicillin | 10,000 UI/ml | 10,000 UI/ml | 5 % |
| Amoxicillin | 20 mg/ml | 20 mg/ml | 5 % |
| Ampicillin | 20 mg/ml | 20 mg/ml | 5 % |
| Cephalosporins | 2 mg/ml | 2 mg/ml | 5 % |
| Anticoagulants | |||
| Heparinsa | undilutedh | 1/10 diluted | undilutedh |
| Heparinoidsb | undilutedh | 1/10 diluted | undilutedh |
| Platinum salts | |||
| Carboplatin | 10 mg/ml | 1 mg/ml | NA |
| Oxaliplatin | 1 mg/ml | 0.1 mg/ml | NA |
| Cisplatin | 1 mg/ml | 0.1 mg/ml | NA |
| NSAIDs | |||
| Pyrazolonesc | Suspensioni | 0,1–1 mg/ml | 10 % |
| Coxibsd | Suspensioni | NA | 10 % |
| Other NSAIDe | Suspensioni | 0.1–1 mg/ml | 10 % |
| Biologicals | |||
| Adalimumab | 50 mg/ml | 50 mg/ml | undilutedh |
| Etanercept | 25 mg/ml | 5 mg/ml | NA |
| Infliximab | 10 mg/ml | 10 mg/ml | NA |
| Omalizumab | 1.25 μg/ml | 1.25 μg/ml | NA |
| Others | |||
| Local anesthetics | Undilutedh | 1/10 diluted | undilutedh |
| Iodinated contrast media | Undilutedh | 1/10 diluted | undilutedh |
| Gadolinium chelates | Undilutedh | 1/10 diluted | NA |
| Patent blue | Undiluted | 1/10 diluted | NA |
| Methylene blue | Undiluted | 1/100 diluted | NA |
| Fluorescein | Undilutedh | 1/10 diluted | undilutedh |
| Proton pump inhibitorsf | Undilutedh | 40 mg/ml | 10 % |
| Anticonvulsantsg | NA | NA | 10 % |
| Chlorhexidine digluconate | 5 mg/ml | 0.002 mg/ml | 1 % |
NA, not applicable or no recommended concentration; NSAID, non-steroidal anti-inflammatory drugs
a Heparins: unfractionated heparin, nadroparin, dalteparin, enoxaparin; testing contraindicated in heparin-induced thrombocytopenia; b heparinoids: danaparoid, fondaparinux; c pyrazolones: metamizole, propyphenazone, aminopyrine, phenazone, phenylbutazone; d coxibs: celecoxib, etoricoxib, valdecoxib; e other NSAIDs: e. g., aspirin, ibuprofen, naproxen, indomethacin, diclofenac, fenoprofen, meloxicam, mefenamic acid, nimesulide; f no intravenous solution available for intradermal testing with lansoprazole and rabeprazole, only for prick testing; g test initially with 1 % in the case of severe reactions; h use of the commercially available solution for intravenous infusion or subcutaneous injection; i tablet is ground to a powder and a suspension prepared using physiological saline solution